Lantern Pharma Inc. (LTRN)

6.31 +0.12 (+1.94%) As of 02:32PM EDT. Market open.

Lantern Pharma Inc.

1920 McKinney Avenue
7th Floor
Dallas, TX 75201
United States
972 277 1136
https://www.lanternpharma.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 21

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Panna Sharma PH.D.	President, CEO & Director	684.38k	N/A	1971
Mr. David R. Margrave	CFO & Secretary	442.68k	N/A	1961
Dr. Kishor Gopaldas Bhatia Ph.D.	Chief Scientific Officer & Scientific Consultant	283.24k	N/A	1955
Nicole Leber	Investor Relations Associate, Finance & Administrative Coordinator	N/A	N/A	N/A
Dr. Peter L. Nara D.V.M., M.S., Ph.D.	Co-Founder & Advisor	N/A	N/A	N/A
Mr. Ernest Kitt B.S., M.S	Head of Clinical Operations	N/A	N/A	N/A

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Lantern Pharma Inc., a clinical stage biotechnology company, focuses on artificial intelligence, machine learning, and genomic data to streamline the drug development process. Its product pipeline comprises LP-300, which is in phase 2 clinical trial in combination therapy for never-smokers with non-small cell lung cancer adenocarcinoma; LP-184, which is in phase 1 clinical trial for the treatment of solid tumor, such as pancreatic, breast, bladder, and lung cancers, and glioblastoma and other central nervous system cancers; and LP-284, which is in phase 1 clinical trial for the treatment of non-Hodgkin's lymphomas, including mantle cell lymphoma and double hit lymphoma. The company develops STAR-001, which is in preclinical development for the treatment of glioblastoma, brain metastases, atypical teratoid rhabdoid tumors, and pediatric rare disease designation. In addition, it provides ADC program, an antibody drug conjugate therapeutic approach for cancer treatment. Further, the company's artificial intelligence platform RADR uses big data analytics and machine learning for combining molecular data. Lantern Pharma Inc. has a strategic AI-driven collaboration with Oregon Therapeutics to optimize the development of its first-in-class protein disulfide isomerase inhibitor drug candidate XCE853 in novel and targeted cancer indications. The company was incorporated in 2013 and is headquartered in Dallas, Texas.

Corporate governance

Lantern Pharma Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.